In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Public ADS offering nets $758mm for BeiGene

Executive Summary

BeiGene (Beijing) Co. Ltd. (immuno-oncology) netted $758mm through the public sale of 7.9mm American Depositary Shares (representing 103mm common; including the overallotment) priced at $101 per ADS. Proceeds will support general corporate needs. Earlier this month, BeiGene announced a commercial supply agreement with Boehringer Ingelheim for manufacturing by BI of BeiGene's tislelizumab (solid and blood cancers), and it also disclosed details of an exclusive licensing deal for Mirati's tyrosine kinase inhibitor sitravatinib (solid tumors including NSCLC).
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register